Argonaute 2 promotes myeloma angiogenesis via microRNA dysregulation by Shuang Wu et al.
JOURNAL OF HEMATOLOGY
& ONCOLOGY
Wu et al. Journal of Hematology & Oncology 2014, 7:40
http://www.jhoonline.org/content/7/1/40RESEARCH Open AccessArgonaute 2 promotes myeloma angiogenesis via
microRNA dysregulation
Shuang Wu1†, Wenjun Yu1†, Xiaoyan Qu1, Rong Wang1, Ji Xu1, Qiguo Zhang2, Jiaren Xu1, Jianyong Li1
and Lijuan Chen1*Abstract
Background: Dysregulated microRNA (miRNA) expression contributes to cancer cell proliferation, apoptosis and
angiogenesis. Angiogenesis is a hallmark of multiple myeloma (MM) development and progression. Argonaute 2
(AGO2) protein, a core component of the RNA-induced silencing complex (RISC), can directly bind to miRNAs and
mediate target messenger RNA (mRNA) degradation. A previous study showed that AGO2 knockdown suppressed
human umbilical vein endothelial cell (HUVEC) growth and tube formation. However, the roles and molecular
mechanisms of AGO2-induced myeloma angiogenesis are not yet fully understood. The aim of this study was to
characterize these roles and effects and their associated mechanisms.
Results: Supernatants from AGO2-overexpressing MM lines induced HUVEC migration and accelerated tube formation.
Conversely, supernatants from AGO2-knockdown MM lines suppressed HUVEC cell migration and tube formation.
Moreover, a chick chorioallantoic membrane (CAM) assay was used to demonstrate that AGO2 could drive neovessel
formation in MM lines in vivo. Using an miRNA microarray, we observed that 25 miRNAs were upregulated
and 7 were downregulated in response to AGO2. Most let-7 family members and 2 miR-17/92 cluster members
(miR-17a and miR-92-1), all known pro-angiogenic miRNAs, were positively regulated by AGO2 whereas
anti-angiogenic miRNAs such as miR-145 and miR-361 were negatively regulated by AGO2.
Conclusions: We conclude that AGO2 can drive neovessel formation in vitro and in vivo by dysregulating the
expression of some angiogenic miRNAs. The pro-angiogenic miRNAs of the let-7 family and the miR-17/92 cluster,
along with the anti-angiogenic miRNA miR-145, play crucial roles in AGO2-mediated angiogenesis by targeting
angiogenesis-related genes.
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Multiple myeloma (MM) is an incurable disease charac-
terized by the clonal proliferation of malignant plasma
cells and increased monoclonal immunoglobulin expres-
sion, along with bone lesions and renal failure. A variety of
chromosomal abnormalities such as translocations, gene
mutations and epigenetic alterations are involved in mye-
lomagenesis [1]. In addition to these oncogenic events,
interactions between MM cells and the bone marrow
microenvironment are well known to play a critical role in* Correspondence: Chenljb@126.com
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unless otherwise stated.MM cell growth, survival, differentiation, migration and
chemotherapeutic resistance [2-4]. The tumour micro-
environment, which comprises a variety of cell types, can
secrete angiogenic cytokines including vascular endothe-
lial growth factor (VEGF), platelet-derived growth factor
(PDGF) and fibroblast growth factor (FGF), thus promot-
ing tumour angiogenesis via endothelial cell (EC) activa-
tion [5,6]. Angiogenesis, a prominent feature of MM, can
predict the prognosis of MM patients and is a hallmark of
MM development and progression [7]. Therefore, anti-
angiogenic therapies such as thalidomide and lenalido-
mide have emerged as essential therapeutic approaches to
this disease [8-10]. Hitherto, although previous studies
have shown that various signalling pathways such as HIF-
1α, Notch1 and PI3K/Akt are involved in MM angiogenesis. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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pletely elucidated.
MicroRNAs (miRNAs or miRs) are small, non-coding,
single-stranded RNAs (approximately 22 nucleotides
long) that regulate protein levels by binding to either
partial or complete complementary sites in messenger
RNAs (mRNAs), thus leading to translational repression
or transcript degradation, respectively [14]. Poliseno
et al. [15] used miRNA microarrays to discover that 27
miRNAs were overexpressed in human umbilical vein
ECs (HUVECs), 15 of which have been found to regulate
angiogenic cytokine expression. In addition, more miR-
NAs with angiogenic roles have been identified. let-7
family member miRNAs have been shown to be pro-
angiogenic and to promote tumour angiogenesis by inhi-
biting the anti-angiogenic factors thrombospondin-1
(TSP-1) and tissue inhibitor of metalloproteinase-1
(TIMP-1) [16,17]. miR-145 inhibits tumour growth and
angiogenesis by targeting N-Ras and VEGF [18]. The miR-
17/92 cluster (which encodes miR-17, −18a, −19a/b, −20a
and −92-1) is overexpressed in tumour cells [19]. Pre-
vious studies revealed that the miR-17/92 cluster
enhanced angiogenesis by downregulating the anti-
angiogenic TSP1 and connective tissue growth factor
(CTGF) [16,20]. Furthermore, this cluster was recently
shown to exhibit anti-angiogenic activity via the in-
hibition of pro-angiogenic genes, including Janus kin-
ase 1 (Jak1) [21] and the integrin subunit alpha 5
(ITG5a) [22].
Drosha and Dicer are 2 key RNase III enzymes that
process pre-miRNAs into mature miRNAs, which are
then incorporated into the RNA-induced silencing
complex (RISC) to downregulate target gene activity by
triggering either RNA degradation or translational re-
pression [23]. Previous studies have reported that Dicer
and Drosha act to drive angiogenesis both in vitro and
in vivo [17,24,25]. In ECs, the downregulation of both
enzymes decreased the capillary-sprouting and tubule-
forming activities induced by regulatory miRNAs, in-
cluding the let-7 family members and miR-27b [17].
The argonaute 2 (AGO2) protein is a core component
of RISC [26]. AGO2 knockdown suppressed HUVEC
growth and tube formation, suggesting that AGO2
also modulates angiogenesis [27,28]. Zhou et al. [29]
reported that in MM patients, increased AGO2 ex-
pression was DNA copy number dependent and that
AGO2 silencing could inhibit cell proliferation and
promote apoptosis in myeloma cell lines. However,
the mechanism by which AGO2 induces angiogenesis
in MM has remained elusive. In the current study, we
discovered that AGO2 can enhance MM angiogenesis
in vitro and in vivo. Further studies revealed that an-
giogenic miRNAs are the key factors that promote
this effect.Results
AGO2 protein expression is associated with microvessel
density (MVD) in MM patients
To investigate the relationship between the AGO2 protein
expression levels and angiogenesis in MM, we detected
the AGO2 protein levels in bone marrow biopsies from
MM patients using an anti-AGO2 antibody and found
that AGO2 protein localized in the myeloma cell cyto-
plasm (Figure 1A). AGO2-high expression (++ to ++++)
was determined in 21 cases and AGO2-low expression
(− or +) in 32 cases. MVD was used to evaluate angiogen-
esis in MM patients. The results showed that MVD was
significantly higher in the AGO2-high expression samples
than in the AGO2-low expression samples (19.24 ± 11.42
vs. 11.97 ± 10.20, p = 0.019; Figure 1B). An analysis of the
correlation coefficients showed that AGO2 expression was
also associated with MVD (r = 0.312, p = 0.023). The data
suggested that AGO2 might enhance angiogenesis in MM
patients.
AGO2 accelerates HUVEC tube formation and migration
in vitro
To validate the pro-angiogenic functional role of AGO2 in
MM, we used lentiviral transfection of an AGO2-shRNA
to silence AGO2 expression in the H929 and LP-1 mye-
loma cell lines (H929-si-AGO2 and LP-1-si-AGO2) and
also generated scramble controls (H929-si-NC and LP-1-
si-NC; Additional file 1: Figure S1). We further established
stable AGO2-overexpressing U266 and OCI-My5 myeloma
cell lines (U266-pcDNA3-AGO2 and OCI-My5-pcDNA3-
AGO2) and empty vector controls (U266-pcDNA3 and
OCI-My5-pcDNA3; Additional file 1: Figure S1). We used
a LUMINEX assay to test a number of angiogenesis-
related cytokines such as matrix metalloproteinases 1, 2,
3, 7, 9, 10, 12 and 13 (MMP-1, 2, 3, 7, 9, 10, 12 and 13,
respectively); FGF-2; PDGF-AA; PDGF-AB/BB; TIMP-
1, 2, 3 and 4; granulocyte-macrophage colony stimulat-
ing factor (GM-CSF); VEGF and epidermal growth fac-
tor (EGF). The results revealed significantly elevated
VEGF protein expression in the supernatants from the
AGO2-overexpressing myeloma cell lines and decreased
expression in the AGO2-knockdown cell lines (Figure 2A).
No significant differences were observed in the MMP-9,
FGF-2 and EGF expression levels (Table 1); the expression
levels of the other cytokines were below the level of detec-
tion. As VEGF can mediate vascular permeability and in-
duce EC growth and vasculogenesis, it thus plays crucial
roles in MM angiogenesis, invasion and metastasis. There-
fore, we further investigated the angiogenic activities
of the supernatants from these AGO2-overexpressing
or -knockdown cell lines.
To investigate the role of AGO2 in EC proliferation,
the supernatants from these AGO2-overexpressing
or -knockdown cell lines and relevant controls were added
Figure 1 AGO2 expression is associated with MVD in MM. (A) Immunohistochemical analysis indicated AGO2 expression in the cytoplasm of
myeloma cells from bone marrow biopsy samples. (B) The MVD was significantly higher in AGO2-high expression (++ to ++++) samples than in
AGO2-low expression (− or +) samples (p = 0.019).
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the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) method at 24, 48, 72, 96 and 120 h. No
significant differences in HUVEC cell proliferation were
observed in response to the supernatants from these cell
lines (Figure 2B).
To assess the potential role of AGO2 activation in EC
migration, a Transwell migration assay was performed to
evaluate the ability of the HUVECs to migrate toward the
supernatants from AGO2-knockdown or -overexpressing
cell lines and relevant controls. The numbers of migrating
HUVECs were 72.33 ± 10.26, 49.67 ± 4.73, 71.67 ± 6.51
and 53.33 ± 7.37 in response to the H929-si-NC, H929-
si-AGO2, LP-1-si-NC and LP-1-si-AGO2 supernatants,
respectively, and 70.33 ± 5.69, 95.67 ± 6.11, 66 ± 5.57
and 100 ± 9.165 in response to the U266-pcDNA3,
U266-pcDNA3-AGO2, OCI-My5-pcDNA3 and OCI-My5-
pcDNA3-AGO2 supernatants, respectively (Figure 2C).
The results indicated that HUVEC migration decreased
when the cells were cultured with supernatants from the
H929 and LP-1 AGO2-knockdown cell lines and in-
creased when the cells were cultured with supernatants
from the AGO2-overexpressing U266 and OCI-My5 cell
lines compared with the relevant controls (p = 0.044461,
0.03265, 0.006357 and 0.009216, respectively). The data
revealed that AGO2 promotes HUVEC migration.
We also observed HUVEC tube formation in vitro.
The results showed that the supernatants from the
AGO2-knockdown H929 and LP-1 cell lines suppressed
HUVEC tube formation at 72 h after incubation com-
pared with that observed with supernatants from the
relevant control cell lines. In contrast, supernatants from
the AGO2-overexpressing U266 and OCI-My5 myeloma
cell lines accelerated tube formation (Figure 2D). Add-
itionally, the tube lengths were calculated using ImagePro
Plus software to yield the following results: 7.33 ± 0.58,
6.67 ± 0.58, 3.67 ± 0.58 and 4.33 ± 1.15 μm/field with theLP-1-Si-NC, H929-Si-NC, U266-pcDNA3 and OCI-My5-
pcDNA3 supernatants, respectively, and 5.33 ± 0.58,
3.33 ± 0.58, 8.33 ± 1.53 and 8.33 ± 2.08 μm/field with the
LP-1-si-AGO2, H929-si-AGO2, U266-pcDNA3-AGO2
and OCI-My5-pcDNA3-AGO2 supernatants, respectively.
The tube lengths decreased significantly when HUVECs
were incubated with supernatants from H929-si-AGO2
and LP-1-si-AGO2 for 72 h and increased in response
to supernatants from U266-pcDNA3-AGO2 and OCI-
My5-pcDNA3-AGO2, relative to the respective con-
trols (p < 0.05; Figure 2E). Taken together, all these
data provide strong evidence that AGO2 can induce
angiogenesis in vitro.
AGO2 facilitates angiogenesis in vivo
A chick chorioallantoic membrane (CAM) assay was used
to assess the effects of AGO2 on angiogenesis in vivo.
Lower blood vessel densities were observed on the CAM
surface at 4 days after infiltration with supernatants from
the H929-si-AGO2 (19 ± 3) and LP-1-si-AGO2 (13 ± 3)
cell lines, compared with infiltration with supernatants
from the H929-si-NC (87 ± 7) and LP-1-si-NC (65 ± 8)
control lines. In contrast, the numbers of infiltrating blood
vessels were significantly higher in response to the super-
natants from the U266-pcDNA3-AGO2 (73 ± 8) and OCI-
My5-pcDNA3-AGO2 (82 ± 6) lines, compared with those
from the U266-pcDNA3 (27 ± 5) and OCI-My5-pcDNA3
(32 ± 4) control lines (Figure 3A,B). These results further
demonstrate the pro-angiogenic effects of AGO2 in vivo.
AGO2 regulates a characteristic miRNA signature in MM
AGO2 is a master regulator of mature miRNA genesis.
To identify specific AGO2-regulated miRNA alterations,
we determined the miRNA microarray profiles of the
H929-si-AGO2, LP-1-si-AGO2, OCI-My5-pcDNA3-AGO2
and U266- pcDNA3-AGO2 lines and the respective con-
trols. Our cut-off criteria for the miRNA expression analysis
Figure 2 (See legend on next page.)
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Figure 2 AGO2 promotes myeloma angiogenesis. (A) VEGF protein expression levels in the supernatants of AGO2-knockdown and overexpressing
myeloma cell lines as determined in a LUMINEX cytokine assay (*p < 0.05, **p < 0.01). (B) HUVEC proliferation and viability in response to culture
with the supernatants from AGO2-knockdown and overexpressing myeloma cell lines were evaluated in an MTT assay. Error bars represent the
standard error of the mean for 2 independent experiments. (C) A Transwell migration assay showed that HUVEC migration decreased in cultures
treated with supernatants from AGO2-knockdown cell lines (upper line) and increased in cultures with supernatants from AGO2-overexpressing
myeloma cell lines (lower line). (D,E) HUVEC tube formation assay. Significant decreases in the tube number (D) and tube length (E) were
observed in co-cultures with supernatants from AGO2-knockdown cell lines compared with those co-cultured with supernatants from scrambled
control lines. Significant increases in the tube number (D) and tube length (E) were also observed in co-cultures with supernatants from
AGO2-overexpressing MM cell lines compared with those co-cultured with supernatants from empty vector control lines (*p < 0.05, **p < 0.01).
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genes, <0.67. We first compared the miRNA microarray
profiles of the H929-si-AGO2 and LP-1-si-AGO2 cell lines
to those of the H929-si-NC and LP-1-si-NC lines, respect-
ively. The analysis revealed that the expression levels of 51,
68, 120 and 97 miRNAs were increased and the levels of
199, 138, 104 and 69 miRNAs were decreased in the H929-
si-AGO2, LP-1-si-AGO2, U266-pcDNA3-AGO2 and OCI-
pcDNA3-AGO2 cell lines, respectively, relative to the levels
in the respective controls. From these data, 100 miRNAs
were down regulated and 8 miRNAs up regulated in the
AGO2-knockdown cell lines whereas 17 miRNAs were
down regulated and 74 miRNAs up regulated in the
AGO2-overexpressing cell lines. Further analysis revealed
that 25 miRNAs were commonly identified as upregulated
and 7 miRNAs as downregulated by AGO2 (Figure 4A,B).
In particular, many of these commonly dysregulated miR-
NAs are well-known angiogenic miRNAs, including the
let-7 family members (let-7a-1, let-7a-2, let-7a-3, let-7b,
let-7f-2, let-7 g and let-7i), 2 miR-17/92 cluster members
(miR-17a and miR-92-1), miR-145 and miR-361.
Validation of the AGO2-mediated dysregulation of
angiogenic miRNA expression via quantitative reverse
transcription–polymerase chain reaction (qRT-PCR)
We additionally performed qRT-PCR to analyse some of
the above-mentioned dysregulated miRNAs and thus val-
idate the microarray results. Consistent with the array
data, let-7a-1, miR-17 and miR-92-1 expression decreased
in the H929-si-AGO2 and LP-1-si-AGO2 cell lines andTable 1 The expression of VEGF, MMP-9, EGF and FGF-2 as de
VEGF (pg/ml) MM
H929/Si-NC 2132.33 ± 328.02 15
H929/SiR-AGO2 194.67 ± 54.12 14
OCI-MY5/pcDNA3 0.92 ± 0.29 12
OCI-MY5/pcDNA3-AGO2 10.36 ± 1.32 13
LP-1/Si-NC 1858.00 ± 368.49 8
LP-1/SiRNA-AGO2 748.56 ± 86.28 9
U266/pcDNA3 164.97 ± 55.62 7
U266/pcDNA3-AGO2 1522.00 ± 209.80 7
Data presented as mean ± s.d. of triplicate samples.
VEGF Vascular endothelial growth factor; MMP-9 Matrix metalloproteinases; EGF Epincreased in the U266-pcDNA3-AGO2 and OCI-My5-
pcDNA3-AGO2 cell lines compared with the respective
controls (p < 0.05). Conversely, miR-145 expression was
increased in the H929-si-AGO2 and LP-1-si-AGO2 cell
lines and decreased in the U266-pcDNA3-AGO2 and
OCI-My5-pcDNA3-AGO2 cell lines (Additional file 1:
Figure S2). These data further confirmed our initial array
results and supported the finding that these miRNAs were
modulated by AGO2.
miR-92-1 targets the angiopoietin-like protein 1
(ANGPTL1), an anti-angiogenic protein with
tumour-inhibiting properties
Previous studies have identified an association between
the critical miR-17/92 cluster genes and pathogenesis
and poor prognosis in MM patients [30,31]. The miR-
17/92 cluster targets the pro-apoptotic gene Bim to sup-
press MM apoptosis [30]. Our findings revealed that
AGO2 increased miR-92-1 expression in MM and thus
contributed to MM angiogenesis. Therefore, we used
available target-prediction software modules (Target
Scan, Pictar) to further identify miR-92-1 targets in-
volved in myeloma angiogenesis. One such targets,
ANGPTL1, was implicated in the negative regulation of
angiogenesis [32]. To explore the relationship between
ANGPTL1, miR-92-1and AGO2 in MM angiogenesis,
we first analysed ANGPTL1 expression in the LP-1-si-
AGO2 cell line and found that it was increased in this
cell line compared with the LP-1-si-NC control line.
Next we added either miR-92-1 mimics or miRNA-NCtected by LUMINEX
P-9 (pg/ml) EGF (pg/ml) FGF-2 (pg/ml)
.03 ± 0.80 48.80 ± 10.42 98.30 ± 16.56
.00 ± 1.65 49.62 ± 4.22 94.86 ± 7.90
.22 ± 1.48 55.96 ± 6.77 81.84 ± 9.04
.49 ± 1.80 53.74 ± 9.45 77.91 ± 5.98
.58 ± 0.85 147.34 ± 17.63 54.37 ± 9.14
.19 ± 0.85 146.77 ± 11.09 50.47 ± 7.19
.99 ± 1.40 177.94 ± 14.40 101.80 ± 13.62
.66 ± 1.27 173.05 ± 16.47 98.87 ± 14.38
idermal growth factor; FGF-2 Fibroblast growth factor-2.
Figure 3 Effects of the supernatants from AGO2-knockdown or -overexpressing MM cell lines on CAM neovascularization. (A) The
supernatants from AGO2-knockdown cell lines inhibited blood vessel formation, whereas those from AGO2-overexpressing cell lines facilitated
blood vessel formation. (B) The number of blood vessels in each CAM (**p < 0.01).
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and Western blotting that ANGPTL1 protein expression
was downregulated in the treated cells compared with
the untreated LP-1-si-AGO2 cells (Figure 5A,B), sug-
gesting that miR-92-1 mimics could abrogate the AGO2-
knockdown-mediated overexpression of ANGPTL1. To
prove that miR-92-1 regulated ANGPTL1 by interacting
with the 3′-UTR of ANGPTL1, we cloned the ANGPTL1
3′-UTR and constructed a corresponding mutant in the
predicted microRNA-binding site. After co-transfection
with pmirGLO-reporter vectors and miR-92-1 mimics,
the LP-1 cells transfected with miR-92-1 mimics exhibited
a significant decline in luciferase activity compared with
the miRNA-NC and mutated-ANGPTL-1 3′-UTR trans-
fected cells (Figure 5C; p < 0.05), indicating that miR-92-1
could regulate ANGPTL1 expression at the transcriptionallevel by interacting with the 3′-UTR of ANGPTL1. These
results demonstrated that ANGPTL1 was a direct target
gene of miR-92-1 and suggested that the miR-92-1-repressing
anti-angiogenic protein ANGPTL1 might contribute to
AGO2-mediated myeloma angiogenesis.
miR-145 targets the pro-angiogenic protein VEGF
Previous studies have revealed that miR-145 inhibits
tumour angiogenesis by directly targeting VEGF [18,33] in
osteosarcoma and breast cancer. Our results also revealed
that VEGF mRNA and protein expression levels in the
miR-145 mimics-transfected U266-pcDNA3-AGO2 cell
line were significantly decreased when compared with those
in cells transfected with miRNA-NC mimics (Figure 6A,B).
The luciferase activity level in U266 cells co-transfected
with pmirGLO-VEGF-3′-UTR and miR-145 mimics was
Figure 4 AGO2-associated miRNA expression profiles. (A) AGO2-regulated miRNAs in AGO2-overexpressing MM lines and (B) AGO2-regulated
miRNAs in AGO2-knockdown MM lines.
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transfected with miRNA-NC or mutated-VEGF-3′-UTR
(Figure 6C). Therefore, the luciferase reporter assay also
demonstrated that VEGF was a direct target gene of miR-
145 in an MM cell line. All these data support a role for
AGO2 in MM angiogenesis in which AGO2 mediates the
miR-145-targeted inhibition of VEGF expression.
let-7a targets HIF-3α, a regulator of VEGF
let-7 family members are known as pro-angiogenic miR-
NAs. Otsuka et al. [16] reported that TIMP-1 was a target
of let-7b. However, the targets of the other let-7 family
members are unclear. Herein, we found that the hypoxia-
inducible factor (HIF)-3α (HIF-3α), a VEGF regulator, was
a target of let-7a according to target-prediction software.
qRT-PCR and Western blotting ascertained that HIF-3α
expression was slightly elevated in the LP-1-si-AGO2 line
but decreased again after the addition of let-7a mimics
(Figure 7A,B). A luciferase reporter assay further demon-
strated that let-7a mimics could inhibit the HIF-3α lucifer-
ase activity (Figure 7C). These results revealed that HIF-3αwas a direct target gene of let-7a and therefore might me-
diate AGO2-induced MM angiogenesis.Discussion
In the current study, we investigated the role of AGO2
in myeloma angiogenesis. AGO2 can directly bind to
miRNAs and thus mediate target mRNA degradation.
Previous studies have validated the connection between
AGO2 and early disease-related death in MM patients
[34], and AGO2 silencing has been shown to inhibit cell
viability in MM cell lines through decreased miR-106a,
miR-106b, miR-17-5p and miR-20b expression and
consequent further activation of the cyclin-dependent
kinase inhibitors p21Waf1/Cip1 and p27Kip1 [29]. Our
study, however, revealed a novel role and mechanism
of AGO2 as an enhancer of myeloma angiogenesis
through miRNA dysregulation, including the upregula-
tion of pro-angiogenic miRNAs such as the let-7 family
members and the miR-17/92 cluster and downregulation
of the anti-angiogenic miRNA miR-145.
Figure 5 miR-92-1 directly targets ANGPTL1. The real-time PCR (A) and Western blot (B) detection of ANGPTL1 expression levels in LP-1-si-AGO2
cells after transfection with negative control and miR-92-1 mimics. (C) The effect of miR-92-1 on the luciferase activities of ANGPTL1 3′-UTR and
ANGPTL1 3′-UTR with a mutated miR-92-1-binding site (mutant UTR, mUTR). miR-92-1 overexpression resulted in a significant decrease in the
pmirGLO-reporter vector luciferase activity with ANGPTL1 3′-UTR but not with the vector containing the corresponding mutant.
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been unclear. AGO2 expression is elevated in colon cancers
[35] and oestrogen receptor (ER) alpha-negative breast can-
cer cell lines [36]. In contrast, other studies have shown
that AGO2 suppressed tumour growth and exhibited anti-
cancer activity [37,38]. Asai et al. [27] first reported that
AGO2 was required for angiogenesis. A robust body of evi-
dence supports the importance of bone marrow angiogen-
esis in MM. Through EC activation, angiogenesis plays an
essential role in tumourigenesis and represents a hallmark
of MM progression [4,39]. In this study, we assessed the as-
sociation between the AGO2 expression levels and MVD in
MM and found a significant positive correlation between
these factors. Furthermore, we studied the effects of AGO2
on HUVEC growth, migration and tube formation in vitro.
Asai et al. [27] revealed that AGO2 silencing in HUVECs
could suppress HUVEC proliferation and tube formation
and trigger apoptosis. Although the present study did not
find that the supernatants from AGO2-overexpressing MM
lines affected HUVEC growth, it did reveal that superna-
tants from AGO2-overexpressing MM lines could induce
HUVEC migration and accelerate tube formation. Con-
versely, the supernatants from AGO2-knockdown MM
lines suppressed HUVEC cell migration and tube forma-
tion. Moreover, a CAM assay was used to demonstrate that
supernatants from the AGO2-overexpressing MM
lines could accelerate blood vessel formation, whereassupernatants from the AGO2-knockdown MM lines
could inhibit blood vessel formation. Consistent with
these findings, AGO2 exerts pro-angiogenic effects on
MM both in vitro and in vivo.
AGO2 acts as a gatekeeper in RNA-silencing pathways
and binds to an miRNA guide strand to mediate target
mRNA cleavage or translational repression [40]. A previ-
ous study showed that elevation of the total miRNA ex-
pression levels in high-risk myeloma cells might be
secondary to AGO2 dysregulation [29]. Using an miRNA
microarray, we observed that 25 miRNAs were commonly
upregulated and 7 miRNAs were commonly downregu-
lated by AGO2. Of interest, the miRNAs regulated posi-
tively by AGO2 included most let-7 family members (let-
7a-1, let-7a-2, let-7a-3, let-7b, let-7f-2, let-7 g and let-7i)
and 2 miR-17/92 cluster members (miR-17a and miR-92-1),
which are known pro-angiogenic miRNAs. Anti-angiogenic
miRNAs such as miR-145 and miR-361 were negatively
regulated by AGO2. Therefore, these miRNAs might con-
tribute to AGO2-mediated MM angiogenesis.
Our study also provided important functional insights
into some of the above-mentioned AGO-dysregulated
angiogenic miRNAs. Previous studies have identified the
miR-17/92 cluster, let-7 family and miR-145 as the mod-
ulators of angiogenesis [41]. The validated targets of the
miR-17/92 cluster include TSP-1, CTGF, TIMP-1 and
ITG5a. miR-92-1 can act through different targets as a
Figure 6 miR-145 directly targets VEGF. The real-time PCR (A) and Western blot (B) detection of VEGF expression levels in U266-pcDNA3-AGO2
cells after transfection with a negative control and miR-145 mimics. (C) The effect of miR-145 on the luciferase activities of VEGF 3′-UTR or VEGF 3′-UTR
with a mutated miR-145-binding site (mUTR). miR-145 overexpression resulted in a significant decrease in the luciferase activity of the
pmirGLO-reporter vector containing the VEGF 3′-UTR but not of the vector containing the corresponding mutant.
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diseases. We first discovered that ANGPTL1, a member
of the angiopoietin-related protein family, was a target
of miR-92-1 in MM cells. ANGPTL1 was identified as
an anti-angiogenic factor that inhibits endothelial cell
migration and tube formation [32,42]. Therefore, miR-
92-1 might serve as a pro-angiogenic factor by sup-
pressing ANGPTL1 expression in AGO2-mediated MM
angiogenesis.
Previous studies have verified that VEGF plays a particu-
larly important role in MM angiogenesis [43]. In this study,
we found that AGO2-overexpressing MM lines facilitated
VEGF protein secretion, whereas AGO2-knockdown MM
lines suppressed VEGF protein secretion. Moreover, we
observed that AGO2 concurrently inhibited miR-145 ex-
pression in MM. Decreased expression of miR-145, which
acts as a tumour suppressor to inhibit the growth, angio-
poiesis and migration of tumour cells, has been observed
in several types of cancer [44-46]. VEGF has been identi-
fied as a key target of miR-145 during the inhibition of
tumour angiogenesis. Herein, we confirmed that miR-145
could downregulate VEGF expression by directly binding
to the 3′-UTR of VEGF, thus suggesting that AGO2 could
accelerate VEGF secretion to promote blood vessel forma-
tion by inhibiting miR-145 expression in MM.Additionally, HIF-1α and HIF-2α drive angiogenesis
during tumour development [47], whereas HIF-3α
negatively regulates the HIF pathway in vascular cells
by decreasing hypoxia-mediated VEGF expression
[48]. For the first time, we used a luciferase activity
assay and Western blotting to validate that HIF-3α
was truly a direct target of let-7a in MM. Therefore,
we suggest that let-7a might promote myeloma angio-
genesis by inhibiting its target (i.e. HIF-3α) and sub-
sequently triggering VEGF expression. Taken together,
these data suggest the strong likelihood that the dys-
regulation of the above-discussed AGO2-induced angio-
genic miRNAs leads to AGO2-mediated angiogenesis
in MM.Conclusions
The present study delineated the mechanistic roles of
AGO2 in MM angiogenesis. AGO2 can drive MM neo-
vessel formation in vitro and in vivo by dysregulating
the expression of some angiogenic miRNAs. The pro-
angiogenic let-7 family miRNAs, the miR-17/92 cluster
and the anti-angiogenic miRNA miR-145 play crucial roles
in AGO2-mediated angiogenesis by targeting angiogenesis-
related genes.
Figure 7 AGO2-related let-7a targets HIF-3α. The real-time PCR (A) and Western blot (B) detection of the HIF-3α expression levels in LP-1-si-AGO2
cells after transfection with a negative control and let-7a mimics. (C) The effect of let-7a on the luciferase activities of HIF-3α 3′-UTR or HIF-3α 3′-UTR
with a mutated let-7a-binding site (mUTR). let-7a overexpression resulted in a significant decrease in the luciferase activity of the pmirGLO-reporter
vector containing the HIF-3α 3′-UTR but not of the vector containing the corresponding mutant.
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Study subjects
This research was approved by the Hospital Review
Board of the First Affiliated Hospital of Nanjing Medical
University. All participants provided written informed
consent in accordance with the Declaration of Helsinki.
Bone marrow biopsy samples were obtained from 53
MM patients (33 males, 22 females) with a median age
of 61.7 years (range, 38–80 years) who were recruited to
this study between July 2010 and January 2013. MM was
diagnosed according to standard morphological and
immunophenotypical criteria. The monoclonal compo-
nent was IgG in 18 cases, IgA in 12 cases, IgD in 1 case,
IgM in 1 case, light chain in 19 cases and no secretion
in 2 cases. According to the Durie–Salmon (DS) staging
system, 5 patients were stage I, 5 were stage II and the
remaining 43 were stage III. According to the Inter-
national Staging System (ISS), 9 patients were stage I, 15
were stage II and the remaining 29 were stage III.
The MM cell lines (LP-1, H929, U266 and OCI-My5)
were gifted from Dr Tian (University of Arkansas for
Medical Science, USA) and cultured in RPMI-1640
media (Gibco, Grand Island, NY, USA). HUVECs were
cultured in ECM media with 10% heat-inactivated foetal
bovine serum (FBS, Gibco), 2-mM L-glutamine (Gibco),
penicillin (100 U/mL) and streptomycin (100 μg/mL) at37°C in a humidified chamber with 95% air and 5% car-
bon dioxide. HUVECs from passages 3–7 were used in
all experiments.
Immunohistochemical analysis and MVD assessment of
bone marrow biopsies
Bone marrow biopsy samples were fixed in 10% formalin
and decalcified in 10% nitric acid. Anti-CD138 was used
to detect myeloma cells. An anti-AGO2 monoclonal
antibody (EAU32; Novocastra Laboratories, Ltd., Newcastle-
upon-Tyne, UK) was used to detect AGO2 expression in
the myeloma cells from these samples. AGO2 staining
was evaluated by 2 independent observers. The immuno-
reactive scores were determined according to the sum of
the stained area and the intensity. Specifically, a score of 0
was assigned to a stained area with 0% reactivity, 1 for an
area with >1% to <10% myeloma cells, 2 for >11% to <50%
myeloma cells, 3 for >51% to <80% myeloma cells and 4
for >81% myeloma cells. For the staining intensity, a score
of 0 was assigned for absent staining, 1 for weak staining,
2 for moderately intense staining and 3 for intense stain-
ing. The combined scores were recorded and graded as
follows: −, 0–3; +, 4–5; ++, 6–8; +++, 9–10 and ++++,
11–12. Blood vessels were labelled with an anti-CD34
antibody (QBEnd10; Novocastra), which immunostained
the EC. MVD was assessed by 2 independent observers.
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identified at 100× magnification, after which the microves-
sels (capillaries and venules) were counted at 400× magni-
fication and the mean microvessels were calculated for the
3 hot spots. The mean count of the 2 independent quanti-
fications was considered the final measurement for each
hot spot.
AGO2 gene overexpression or knockdown in MM cell
lines
Synthetic double-stranded oligonucleotide sequences en-
coding the AGO2-shRNA and scramble control siRNA
were described previously [29]; these were cloned into len-
tiviral pSRL-SIH1 vectors. Recombinant lentivirus was
produced by transfecting 293 T cells according to a stand-
ard protocol. Lentiviral AGO2 shRNA and scramble
(SCR) shRNA were produced in 293 T packaging cells,
concentrated at a multiplicity of infection (MOI) of 50
and individually added to H929 and LP-1 cell suspensions
in the presence of 5 g/mL of polybrene. All transfection
experiments were performed in duplicate.
The amplified 2580-bp AGO2 cDNA sequence (forward
primer: 5′-CGCGAATTCATGTAC TCGGGAGCCGGC
C-3′, reverse primer: 5′-GCTCTAGATCAAGCAAAGTA
CATGGTG-3′) was cloned into the pcDNA3 vector to
construct the pcDNA3-AGO2 expression plasmid.
pcDNA3-AGO2 and pcDNA3 empty vector (EV) plas-
mids were transfected into U266 and OCI-My5 cell lines
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA,
USA); transfections were performed in 6-well plates.
After a 72-h incubation, G418 (Invitrogen; 400 μg/ml)
was used to select G418-resistant cells. Stable AGO2-
overexpressing U266 and OCI-My5 clones were estab-
lished after 3 months. Stable EV clones of the 2 cell lines
were also constructed and served as controls.
Cell proliferation assay
Pancreatin-digested HUVECs were added to 96-well plates
at a density of 5 × 103 cells/well and were incubated with
supernatants from AGO2-knockdown or -overexpressing
myeloma cells. An MTT colorimetric assay was per-
formed to evaluate the cell viability at 24, 48, 72, 96
and 120 h. Twenty microlitres of MTT (5 mg/ml) were
added to each well. After a 4-h incubation, the super-
natant fluid was discarded and 100 μl of DMSO were
added to each well. The absorbance intensity was measured
at 490 nm with a microplate reader (BioTek, Winooski,
VT, USA).
Transwell migration assay
To evaluate EC migration, a 24-well Transwell plate
(Corning Costar, Corning, NY, USA) with an 8.5-μm
polycarbonate membrane was used. The undersurface of
the Transwell was coated with 10 μg/ml of collagen I(Sigma, St. Louis, MO, USA). HUVECs were seeded in
the upper chambers in 100 μl of 10% FBS RPMI-1640
medium; 600 μl of supernatants from AGO2-knockdown
or -overexpressing myeloma cells were added to the lower
chambers. SCR shRNA and pcDNA3-EV-transfected mye-
loma cell line supernatants were used as controls. After a
24-h incubation at 37°C and 5% CO2, the non-migrating
HUVECs on the upper sides of the membranes were
removed, and the migrated cells on the lower sides of
the membranes were stained with crystal violet and
counted under an Olympus optical microscope (Olympus
Corporation, Tokyo, Japan).
Tube formation assay
The HUVEC tube formation assay was performed ac-
cording to the manufacturer’s instructions. Trypsinized
HUVECs (1 × 104) were seeded onto a Matrigel-coated
(BD Biosciences, San Jose, CA, USA) 24-well plate and
incubated with cell-free culture supernatants from AGO2-
knockdown or -overexpressing myeloma cells and controls
at 37°C and 5% CO2 for 72 h. The degree of tube formation
was evaluated using an inverted microscope. The numbers
of tubes were calculated using ImagePro Plus software
(Media Cybernetics Inc., Rockville, MD, USA).
CAM assay
A CAM assay [49] was performed to determine the an-
giogenic activity of AGO2 in vivo. Fertilized 7-day-old
chicken eggs were obtained from a local hatchery. A
small (0.6 × 1.0 cm) window was made on each shell,
and a 0.5-cm diameter sterile filter paper soaked with
AGO2-knockdown or -overexpressing myeloma cell super-
natant was loaded onto each CAM. The windows were
then sealed with sterile tape and the eggs were incu-
bated at 37.5°C. Following an additional 96-h incuba-
tion, images of each treated CAM were captured under
a dissecting microscope, and the blood vessels in 5 filter
paper fields were counted at 40× magnification to evalu-
ate angiogenesis.
miRNA microarray data analysis
Total RNA was extracted from the myeloma cell lines
using TRIzol (Invitrogen). A total of 640 DNA oligo-
nucleotide probes from the mirVana miRNA Probe Set
(Ambion/Life Technologies, Carlsbad, CA, USA) were
designed according to the sequences of their respective
mature miRNAs. The probes were resuspended at a con-
centration of 50 mM in 3× saline sodium citrate (SSC)
and spotted onto MICROMAX SuperChip I Glass Slides
(PerkinElmer Inc., Waltham, MA, USA) in duplicates at
50%–60% humidity, using a SpotArray 24 Microarray
Printing System (PerkinElmer). Small RNAs were labelled
with Cy5 or Cy3 dyes (Amersham Biosciences, Piscataway,
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(Ambion/Life Technologies). After an overnight (12–
16 h) hybridization at 42°C, the slides were washed in
SSC and scanned with a ScanArray Express Microarray
Scanner and ScanArray 3.0 software (PerkinElmer).
A >1.5-fold increase or a <0.67-fold decrease in the ex-
pression level was set as the threshold to indicate a signifi-
cant change.miRNA quantitative RT-PCR (qPCR) analysis
miRNA qRT-PCR was performed with the SYBR Premix
Ex TaqTM kit according to the manufacturer’s recom-
mendations, and qRT-PCR was performed on an iQ5
real-time PCR detection system (Bio-Rad Laboratories
Inc., Hercules, CA, USA). The relative gene expression
levels were calculated according to the 2−ΔΔCt method.
All primers were purchased from Genewiz, Inc. (Suzhou,
China). Each sample was normalized to the mean U6 ex-
pression value. Comparative real-time PCR was performed
in triplicate throughout the study.miRNA oligonucleotide mimics transfection experiments
miRNA oligonucleotide mimics were designed and
synthesized by GenePharma (Shanghai, P.R. China)
and transfected into LP-1 cell lines using Lipofecta-
mine 2000 (Invitrogen). The mimic sequences were as
follows: miRNA-negative control (miRNA-NC) mimics,
UUCUCCGAACGUGUCACGUTT, ACGUGACACGUU
CGGAGAATT; hsa-mir-92-1 mimics, AGGUUGGGAU
CGGUUGCAAUGCU, AGCAUUGCAACCGAUCCCAA
CCU; hsa-let-7a mimics, UGAGGUAGUAGGUUGUAUA
GUU, AACUAUACAACCUACUACCUCA and hsa-mir-
145 mimics, GUCCAGUUUUCCCAGGAAUCCCU, AG
GGAUUCCUGGGAAAACUGGAC. Each experiment was
performed in triplicate.Luciferase reporter assay
The ANGPTL1-3′-UTR, HIF-3α-3′-UTR and VEGF-3′-
UTR sequences and corresponding mutated sequences
were cloned into the pmirGLO Dual-Luciferase miRNA
Target Expression Vector. LP-1 or U266 myeloma cells
were co-transfected with the different cloned pmirGLO
(0.2 μg) plasmids and miRNA mimics (10 pmol) using Li-
pofectamine 2000 (Invitrogen). The cells were harvested
after 48 h and analysed with the Dual Luciferase Reporter
Assay kit (Promega, Madison, WI, USA) according to the
manufacturer’s recommendations. Firefly and Renilla lu-
ciferase activities were quantified in the cell lysates. The
luciferase readings were corrected for background, and
the firefly luciferase values were normalized to the Renilla
values to control for transfection efficiency. All assays
were performed in triplicate.Western blot analysis
Western blots were performed as previously described
[19]. Briefly, cells were lysed with a lysis buffer for 30 min
on ice. Fifty micrograms of protein were fractionated via
10% SDS-PAGE and transferred onto nitrocellulose mem-
branes (EMD Millipore, Billerica, MA, USA). The mem-
branes were then probed with appropriate primary
antibodies (1:500 dilution), including anti-AGO2, anti-
VEGF, anti-ANGPTL1, anti-HIF-3α and anti-tubulin anti-
bodies (Abcam, Cambridge, UK), followed by incubation
with HRP-conjugated secondary antibodies (1:5000 dilu-
tion). The probed proteins were then detected with an en-
hanced chemiluminescent substrate (NEL100001EA;
PerkinElmer). The tubulin expression level served as an
internal control.
LUMINEX cytokine assay
The LUMINEX assay was performed on a Luminex
FLEX MAP 3D platform with the MILLIPLEX MAP
Human Cytokine/Chemokine Panel (Millipore, USA) ac-
cording to the manufacturer’s instructions. We detected
a variety of cytokines (MMP-1, MMP-2, MMP-3, MMP-7,
MMP-9, MMP-10, MMP-12, MMP −13, FGF-2, PDGF-
AA, PDGF-AB/BB, TIMP-1, TIMP-2, TIMP-3, TIMP-4,
GM-CSF, VEGF and EGF). The analysis of cytokine ex-
pression in the supernatants from the AGO2-knockdown
and overexpressing myeloma cell lines was also performed
in triplicate; all values were calculated via extrapolation
from the standard curve.
Statistical analysis
The statistical analysis was performed using GraphPad
Prism 5 software (GraphPad, Inc., San Diego, CA, USA).
The numerical results are expressed as means ± standard
deviations. The differences in the results among the groups
were statistically analysed using the unpaired Student's t
test and the Mann–Whitney U-test. Correlations of
AGO2 with MVD were performed using Spearman’s
correlation. P values of <0.05 were considered statisti-
cally significant.
Additional file
Additional file 1: Figure S1. AGO2 protein expression in
AGO2-knockdown and -overexpression myeloma cell lines. Figure S2. The
relative expression of AGO2-regulated miRNAs in AGO2 knockdown or
over-expression myeloma cell lines by RT- PCR. (A) miR-17 expression; (B)
miR-92-1 expression; (C) miR-145 expression; (D) Let-7a expression. Table S1.
The normal and mutated sequence of predicted miRNAs-binding site in
target gene 3’UTR.
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